Skip to main content
Edwards Lifesciences Logo

RESILIA tissue surgical valve portfolio

Discover the RESILIA tissue portfolio difference

PROVEN IMG

Proven PERIMOUNT Platform

RESILIA Tissue Durabilityimg

RESILIA Tissue Durability

Future Focused img

Future  Focused

Innovation built on a proven platform

RESILIA tissue valves are built on the Carpentier-Edwards PERIMOUNT valve platform, whose performance is backed by 30 years of durability data, including the largest long-term study of a bioprosthetic valve.

Innovation built on a proven platform IMG

Innovation that transformed the tissue valve landscape

RESILIA tissue technology

RESILIA tissue* builds on the trusted ThermaFix‡ process and is treated with a novel preservation technology to resist calcification more effectively and allow for dry storage.1

img

+ Calcium-blocking technology

Stable-capping permanently blocks free aldehydes to prevent calcium binding within the tissue

img

+ Glycerolization

Mitigates calcium-attracting glutaraldehyde residuals and enables dry tissue storage for increased ease of use

72% less calcium content after 8 months

RESILIA tissue showed significant improvement in calcium-blocking properties1


(follow-up exceeded the 5-month duration required by regulatory agencies)
img

‡No clinical data are available which evaluate the long-term impact of the Carpentier-Edwards ThermaFix treatment in patients.

*Clinical data on surgical valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10-years in progress2
†RESILIA tissue tested against tissue from commercially available bovine pericardial valves from Edwards in a juvenile sheep model. Flameng, et al. J Thorac Cardiovasc Surg. 2015;149:340-345. 


a. 6900P is an older valve model being discontinued and is not available for commercial use.

Taking performance and durability to new heights

The RESILIA tissue surgical valve portfolio is backed by a robust, growing base of clinical evidence attesting to its hemodynamic performance and durability. RESILIA tissue has been applied to INSPIRIS and MITRIS valves.

IMG

Clinically stable hemodynamics2,3

img
img

Durability data2,3

img
img

RESILIA tissue valves showed less SVD-related HVD vs conventional valves in a comparison of COMMENCE and PARTNER IIA trials4

See the clinical evidence

Innovation that keeps future procedures in mind

1 / 4
Expanding patient possibilities with VFit technology
Largest opening area, with the lowest gradients
Designed to prevent obstruction
Delivering the best visibility for future interventions
Expanding patient possibilities with VFit technology

Expanding patient possibilities with VFit technology

Largest opening area, with the lowest gradients

Largest opening area, with the lowest gradients

Designed to prevent obstruction

Designed to prevent obstruction

Delivering the best visibility for future interventions

Delivering the best visibility for future interventions

Expanding patient possibilities with VFit technology

Largest opening area, with the lowest gradients

Designed to prevent obstruction

Delivering the best visibility for future interventions

Featured Products

Explore our current RESILIA tissue products

inspiris resilia

INSPIRIS RESILIA aortic valve

KONECT RESILIA

KONECT RESILIA aortic valved conduit

mitris resilia thumb

MITRIS RESILIA mitral valve

Resources

At the cutting edge of innovation

RESILIA tissue portfolio

Download brochure
inspiris thumbnail

INSPIRIS RESILIA aortic valve

Download fact sheet
konect thumbnail

KONECT RESILIA aortic valved conduit

Download fact sheet
MITRIS fact sheet

MITRIS RESILIA mitral valve

Download fact sheet

References

  1. Flameng W, Hermans H, Verbeken E, et al. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149(1):340-345. 
  2. Beaver T, Bavaria J, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2023;x:1-11. 
  3. Heimansohn DA, Baker C, Rodriguez E, et al. Mid-term outcomes of the COMMENCE trial investigating mitral valve replacement using a bioprosthesis with a novel tissue. JTCVS Open. 2023;15:151-163. 
  4. Bartus K, Bavaria J, Thourani V, et al. Structural hemodynamic valve deterioration durability of RESILIA-tissue versus contemporary aortic bioprostheses. J Comp Eff Res. 2023;12(3):e220180. 
  5. Saxon JT, Allen K, Cohen D, et al. Bioprosthetic valve fracture during valve-in-valve TAVR: bench to bedside. Interv Cardiol. 2018;13(1):20-26. 
  6. Saxon JT, Allen K, Cohen D, et al. Complications of bioprosthetic valve fracture as an adjunct to valve-in-valve TAVR. Structural Heart. 2019;3(2):92-99. 
  7. Wang DD, O’Neill B, Caranasos T, et al. Comparative differences of mitral valve-in-valve implantation: A new mitral bioprosthesis versus current mosaic and epic valves. Catheter Cardiovasc Interv. 2022;99(3):934-942.

Clinical data on surgical valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up to 10-years in progress2.

*Refer to device instructions for important warnings related to VFit technology. These features have not been observed in clinical studies to establish the safety and effectiveness of the model 11500A for use in valve-in-valve procedures. VFit technology is available on sizes 19–25 mm.

Medical device for professional use

Medical device for professional use

For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).